UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 171

Sortiert nach

Denosumab Compared With Zoledronic Acid for the Treatment of Bone Metastases in Patients With Advanced Breast Cancer: A Randomized, Double-Blind Study

Journal of clinical oncology, 2010-12, Vol.28 (35), p.5132-5139

2010

Link zum Volltext

Verfügbarkeit prüfen

Osteoclast inhibition in postmenopausal breast cancer: Is the evidence too strong to ignore?

Cancer, 2017-07, Vol.123 (13), p.2392-2394

Stopeck, Alison T.

2017

Link zum Volltext

Verfügbarkeit prüfen

Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years

The New England journal of medicine, 2016-07, Vol.375 (3), p.209-219

2016

Link zum Volltext

Verfügbarkeit prüfen

Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: A combined analysis of 3 pivotal, randomised, phase 3 trials

European journal of cancer (1990), 2012-11, Vol.48 (16), p.3082-3092

2012

Link zum Volltext

Verfügbarkeit prüfen

Changes in serum estradiol levels with Estring in postmenopausal women with breast cancer treated with aromatase inhibitors

Supportive care in cancer, 2021, Vol.29 (1), p.187-191

2021

Link zum Volltext

Verfügbarkeit prüfen

Combination of Trastuzumab and Tanespimycin (17-AAG, KOS-953) Is Safe and Active in Trastuzumab-Refractory HER-2–Overexpressing Breast Cancer: A Phase I Dose-Escalation Study

Journal of clinical oncology, 2007-12, Vol.25 (34), p.5410-5417

2007

Link zum Volltext

Verfügbarkeit prüfen

Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer

Supportive care in cancer, 2016-01, Vol.24 (1), p.447-455

2016

Link zum Volltext

Verfügbarkeit prüfen

Response to letter to the Editors—Safety of long-term denosumab therapy

Supportive care in cancer, 2017-02, Vol.25 (2), p.353-355

2017

Link zum Volltext

Verfügbarkeit prüfen

Blood plasma derived extracellular vesicles (BEVs): particle purification liquid chromatography (PPLC) and proteomic analysis reveals BEVs as a potential minimally invasive tool for predicting response to breast cancer treatment

Breast cancer research and treatment, 2022-11, Vol.196 (2), p.423-437

2022

Link zum Volltext

Verfügbarkeit prüfen

EMERGE: A Randomized Phase II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Advanced Glycoprotein NMB-Expressing Breast Cancer

Journal of clinical oncology, 2015-05, Vol.33 (14), p.1609-1619

2015

Link zum Volltext

Verfügbarkeit prüfen

Phase III Randomized Trial of Bisphosphonates as Adjuvant Therapy in Breast Cancer: S0307

JNCI : Journal of the National Cancer Institute, 2020-07, Vol.112 (7), p.698-707

2020

Link zum Volltext

Verfügbarkeit prüfen

Randomized, Placebo-Controlled, Double-Blind, Phase II Study of Axitinib Plus Docetaxel Versus Docetaxel Plus Placebo in Patients With Metastatic Breast Cancer

Journal of clinical oncology, 2011-06, Vol.29 (18), p.2459-2465

2011

Link zum Volltext

Verfügbarkeit prüfen

Sulindac, a Nonselective NSAID, Reduces Breast Density in Postmenopausal Women with Breast Cancer Treated with Aromatase Inhibitors

Clinical cancer research, 2021-10, Vol.27 (20), p.5660-5668

2021

Link zum Volltext

Verfügbarkeit prüfen

Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast Cancer

The New England journal of medicine, 2004-08, Vol.351 (8), p.781-791

2004

Link zum Volltext

Verfügbarkeit prüfen

Circulating Tumor Cells at Each Follow-up Time Point during Therapy of Metastatic Breast Cancer Patients Predict Progression-Free and Overall Survival

Clinical cancer research, 2006-07, Vol.12 (14), p.4218-4224

2006

Link zum Volltext

Verfügbarkeit prüfen

The role of denosumab in the prevention of hypercalcaemia of malignancy in cancer patients with metastatic bone disease

European journal of cancer (1990), 2015-07, Vol.51 (11), p.1467-1475

2015

Link zum Volltext

Verfügbarkeit prüfen

Circulating Tumor Cells: A Novel Prognostic Factor for Newly Diagnosed Metastatic Breast Cancer

Journal of clinical oncology, 2005-03, Vol.23 (7), p.1420-1430

2005

Link zum Volltext

Verfügbarkeit prüfen

Case report: Metastatic metaplastic breast cancer with choriocarinomatous features: Targeting the choriocarcinoma component for cure

Frontiers in oncology, 2023-01, Vol.12, p.1061679

2023

Link zum Volltext

Verfügbarkeit prüfen

Changes in Bone Turnover Marker Levels and Clinical Outcomes in Patients with Advanced Cancer and Bone Metastases Treated with Bone Antiresorptive Agents

Clinical cancer research, 2016-12, Vol.22 (23), p.5713-5721

2016

Link zum Volltext

Verfügbarkeit prüfen

Sulindac Improves Stiffness and Quality of Life in Women Taking Aromatase Inhibitors for Breast Cancer

Breast cancer research and treatment, 2022-02, Vol.192 (1), p.113-122

2022

Link zum Volltext

Verfügbarkeit prüfen

Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801

Blood, 2007-06, Vol.109 (12), p.5136-5142

2007

Link zum Volltext

Verfügbarkeit prüfen

Bone-Related Complications and Quality of Life in Advanced Breast Cancer: Results from a Randomized Phase III Trial of Denosumab versus Zoledronic Acid

Clinical cancer research, 2012-09, Vol.18 (17), p.4841-4849

2012

Link zum Volltext

Verfügbarkeit prüfen

Reproducible automated breast density measure with no ionizing radiation using fat‐water decomposition MRI

Journal of magnetic resonance imaging, 2018-10, Vol.48 (4), p.971-981

2018

Link zum Volltext

Verfügbarkeit prüfen

Risk factors associated with skeletal-related events following discontinuation of denosumab treatment among patients with bone metastases from solid tumors: A real-world machine learning approach

Journal of bone oncology, 2022-06, Vol.34, p.100423-100423, Article 100423

2022

Link zum Volltext

Verfügbarkeit prüfen

Assessment of carbonic anhydrase IX expression and extracellular pH in B-cell lymphoma cell line models

Leukemia & lymphoma, 2015-05, Vol.56 (5), p.1432-1439

2015

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 171

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(161)
Mit Volltextzugriff
(162)

Publikationsform

Sprache

Englisch
(170)
Japanisch
(10)
Russisch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Denosumab Compared With Zoledronic Acid for the Treatment of Bone Metastases in Patients With Advanced Breast Cancer: A Randomized, Double-Blind Study

Osteoclast inhibition in postmenopausal breast cancer: Is the evidence too strong to ignore?

Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years

Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: A combined analysis of 3 pivotal, randomised, phase 3 trials

Changes in serum estradiol levels with Estring in postmenopausal women with breast cancer treated with aromatase inhibitors

Combination of Trastuzumab and Tanespimycin (17-AAG, KOS-953) Is Safe and Active in Trastuzumab-Refractory HER-2–Overexpressing Breast Cancer: A Phase I Dose-Escalation Study

Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer

Response to letter to the Editors—Safety of long-term denosumab therapy

Blood plasma derived extracellular vesicles (BEVs): particle purification liquid chromatography (PPLC) and proteomic analysis reveals BEVs as a potential minimally invasive tool for predicting response to breast cancer treatment

EMERGE: A Randomized Phase II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Advanced Glycoprotein NMB-Expressing Breast Cancer

Phase III Randomized Trial of Bisphosphonates as Adjuvant Therapy in Breast Cancer: S0307

Randomized, Placebo-Controlled, Double-Blind, Phase II Study of Axitinib Plus Docetaxel Versus Docetaxel Plus Placebo in Patients With Metastatic Breast Cancer

Sulindac, a Nonselective NSAID, Reduces Breast Density in Postmenopausal Women with Breast Cancer Treated with Aromatase Inhibitors

Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast Cancer

Circulating Tumor Cells at Each Follow-up Time Point during Therapy of Metastatic Breast Cancer Patients Predict Progression-Free and Overall Survival

The role of denosumab in the prevention of hypercalcaemia of malignancy in cancer patients with metastatic bone disease

Circulating Tumor Cells: A Novel Prognostic Factor for Newly Diagnosed Metastatic Breast Cancer

Case report: Metastatic metaplastic breast cancer with choriocarinomatous features: Targeting the choriocarcinoma component for cure

Changes in Bone Turnover Marker Levels and Clinical Outcomes in Patients with Advanced Cancer and Bone Metastases Treated with Bone Antiresorptive Agents

Sulindac Improves Stiffness and Quality of Life in Women Taking Aromatase Inhibitors for Breast Cancer

Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801

Bone-Related Complications and Quality of Life in Advanced Breast Cancer: Results from a Randomized Phase III Trial of Denosumab versus Zoledronic Acid

Reproducible automated breast density measure with no ionizing radiation using fat‐water decomposition MRI

Risk factors associated with skeletal-related events following discontinuation of denosumab treatment among patients with bone metastases from solid tumors: A real-world machine learning approach

Assessment of carbonic anhydrase IX expression and extracellular pH in B-cell lymphoma cell line models

Suchergebnisse filtern